This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Alam H., Gu B., Lee M.G.: Histone methylation modifiers in cellular signaling pathways. Cell. Mol. Life Sci., 2015; 72: 4577–4592AlamH.GuB.LeeM.G.Histone methylation modifiers in cellular signaling pathwaysCell. Mol. Life Sci.2015724577459210.1007/s00018-015-2023-ySearch in Google Scholar
Amano Y., Matsubara D., Yoshimoto T., Tamura T., Nishino H., Mori Y., Niki T.: Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition. Pathol. Int., 2018; 68: 359–366AmanoY.MatsubaraD.YoshimotoT.TamuraT.NishinoH.MoriY.NikiT.Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transitionPathol. Int.20186835936610.1111/pin.12666Search in Google Scholar
Baldwin R.M., Bejide M., Trinkle-Mulcahy L., Côté J.: Identification of the PRMT1v1 and PRMT1v2 specific interactomes by quantitative mass spectrometry in breast cancer cells. Proteomics, 2015; 15: 2187–2197BaldwinR.M.BejideM.Trinkle-MulcahyL.CôtéJ.Identification of the PRMT1v1 and PRMT1v2 specific interactomes by quantitative mass spectrometry in breast cancer cellsProteomics2015152187219710.1002/pmic.201400209Search in Google Scholar
Baldwin R.M., Haghandish N., Daneshmand M., Amin S., Paris G., Falls T.J., Bell J.C., Islam S., Côté J.: Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression. Oncotarget, 2015; 6: 3013–3032BaldwinR.M.HaghandishN.DaneshmandM.AminS.ParisG.FallsT.J.BellJ.C.IslamS.CôtéJ.Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expressionOncotarget201563013303210.18632/oncotarget.3072Search in Google Scholar
Banasavadi-Siddegowda Y.K., Welker A.M., An M., Yang X., Zhou W., Shi G., Imitola J., Li C., Hsu S., Wang J., Phelps M., Zhang J., Beattie C.E., Baiocchi R., Kaur B.: PRMT5 as a druggable target for glioblastoma therapy. Neuro Oncol., 2018; 20: 753–763Banasavadi-SiddegowdaY.K.WelkerA.M.AnM.YangX.ZhouW.ShiG.ImitolaJ.LiC.HsuS.WangJ.PhelpsM.ZhangJ.BeattieC.E.BaiocchiR.KaurB.PRMT5 as a druggable target for glioblastoma therapyNeuro Oncol.20182075376310.1093/neuonc/nox206Search in Google Scholar
Bedford M.T.: The family of protein arginine methyltransferases. The Enzymes, 2006; 24: 31–50BedfordM.T.The family of protein arginine methyltransferasesThe Enzymes200624315010.1016/S1874-6047(06)80004-1Search in Google Scholar
Behera A.K., Kumar M., Shanmugam M.K., Bhattacharya A., Rao V.J., Bhat A., Vasudevan M., Gopinath K.S., Mohiyuddin A., Chatteriee A., Sethi G., Kundu T.K.: Functional interplay between YY1 and CARM1 promotes oral carcinogenesis. Oncotarget, 2019; 10: 3709–3724BeheraA.K.KumarM.ShanmugamM.K.BhattacharyaA.RaoV.J.BhatA.VasudevanM.GopinathK.S.MohiyuddinA.ChatterieeA.SethiG.KunduT.K.Functional interplay between YY1 and CARM1 promotes oral carcinogenesisOncotarget2019103709372410.18632/oncotarget.26984655720531217904Search in Google Scholar
Brehmer D., Wu T., Mannens G., Beke L., Vinken P., Gaffney D., Sun W., Pande V., Thuring J.W., Millar H., Poggesi I., Somers I., Boeckx A., Parade M., van Heerde E. i wsp.: Abstract DDT02-04: A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models. Cancer Res., 2017; 77: DDT02–04BrehmerD.WuT.MannensG.BekeL.VinkenP.GaffneyD.SunW.PandeV.ThuringJ.W.MillarH.PoggesiI.SomersI.BoeckxA.ParadeM.van HeerdeE.Abstract DDT02-04: A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer modelsCancer Res.201777DDT020410.1158/1538-7445.AM2017-DDT02-04Search in Google Scholar
Carlson S.M., Gozani O.: Emerging technologies to map the protein methylome. J. Mol. Biol. 2014; 426: 3350–3362CarlsonS.M.GozaniO.Emerging technologies to map the protein methylomeJ. Mol. Biol.20144263350336210.1016/j.jmb.2014.04.024417730124805349Search in Google Scholar
Carr S.M., Roworth A.P., Chan C., La Thangue N.B.: Post-translational control of transcription factors: Methylation ranks highly. FEBS J., 2015; 282: 4450–4465CarrS.M.RoworthA.P.ChanC.La ThangueN.B.Post-translational control of transcription factors: Methylation ranks highlyFEBS J.20152824450446510.1111/febs.1352426402372Search in Google Scholar
Castellano S., Milite C., Ragno R., Simeoni S., Mai A., Limongeli V., Novellino E., Bauer I., Brosh G., Spannhoff A., Cheng D., Bedford M.T., Sbardella G.: Design, synthesis and biological evaluation of carboxy analogues of argininę methyltransferase inhibitor 1 (AMI-1). ChemMedChem., 2010; 5: 398–414CastellanoS.MiliteC.RagnoR.SimeoniS.MaiA.LimongeliV.NovellinoE.BauerI.BroshG.SpannhoffA.ChengD.BedfordM.T.SbardellaG.Design, synthesis and biological evaluation of carboxy analogues of argininę methyltransferase inhibitor 1 (AMI-1)ChemMedChem.2010539841410.1002/cmdc.20090045920091730Search in Google Scholar
Cheng D., Yadav N., King R.W., Swanson M.S., Weinstein E.J., Bedford M.T.: Small molecule regulators of protein arginine methyltransferases. J. Biol. Chem., 2004; 279: 23892–23899ChengD.YadavN.KingR.W.SwansonM.S.WeinsteinE.J.BedfordM.T.Small molecule regulators of protein arginine methyltransferasesJ. Biol. Chem.2004279238922389910.1074/jbc.M40185320015056663Search in Google Scholar
Eram M.S., Shen Y., Szewczyk M., Wu H., Senisterra G., Li F., Butler K.V., Kaniskan H.Ü., Speed B.A., Dela Seña C., Dong A., Zeng H., Schapira M., Brown P.J., Arrowsmith C.H. i wsp.: A potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases. ACS Chem. Biol., 2016; 11: 772–781EramM.S.ShenY.SzewczykM.WuH.SenisterraG.LiF.ButlerK.V.KaniskanH.Ü.SpeedB.A.Dela SeñaC.DongA.ZengH.SchapiraM.BrownP.J.ArrowsmithC.H.A potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferasesACS Chem. Biol.20161177278110.1021/acschembio.5b00839479891326598975Search in Google Scholar
Feng Y., Xie N., Wu J., Yang C., Zheng Y.G.: Inhibitory study of protein arginine methyltransferase 1 using a fluorescent approach. Biochem. Biophys. Res. Commun., 2009; 379: 567–572FengY.XieN.WuJ.YangC.ZhengY.G.Inhibitory study of protein arginine methyltransferase 1 using a fluorescent approachBiochem. Biophys. Res. Commun.200937956757210.1016/j.bbrc.2008.12.11919121292Search in Google Scholar
Fulton M.D., Brown T., Zheng Y.G.: Mechanisms and inhibitors of histone arginine methylation. Chem. Rec., 2018; 18: 1792–1807FultonM.D.BrownT.ZhengY.G.Mechanisms and inhibitors of histone arginine methylationChem. Rec.2018181792180710.1002/tcr.201800082634810230230223Search in Google Scholar
Geng P., Zhang Y., Liu X., Zhang N., Liu Y., Liu X., Lin C., Yan X., Li Z., Wang G., Li Y., Tan J., Liu D.X., Huang B., Lu J.: Automethylation of protein arginine methyltransferase 7 and its impact on breast cancer progression. FASEB J., 2017; 31: 2287–2300GengP.ZhangY.LiuX.ZhangN.LiuY.LiuX.LinC.YanX.LiZ.WangG.LiY.TanJ.LiuD.X.HuangB.LuJ.Automethylation of protein arginine methyltransferase 7 and its impact on breast cancer progressionFASEB J.2017312287230010.1096/fj.201601196R28188177Search in Google Scholar
Hadjikyriacou A., Yang Y., Espejo A., Bedford M.T., Clarke S.G.: Unique features of human protein arginine methyltransferase 9 (PRMT9) and its substrate RNA splicing factor SF3B2. J. Biol. Chem., 2015; 290: 16723–16743HadjikyriacouA.YangY.EspejoA.BedfordM.T.ClarkeS.G.Unique features of human protein arginine methyltransferase 9 (PRMT9) and its substrate RNA splicing factor SF3B2J. Biol. Chem.2015290167231674310.1074/jbc.M115.659433450542225979344Search in Google Scholar
Haghandish N., Baldwin R.M., Morettin A., Dawit H.T., Adhikary H., Masson J.Y., Mazroui R., Trinkle-Mulcahy L., Côté J.: PRMT7 methylates eukaryotic translation initiation factor 2α and regulates its role in stress granule formation. Mol. Biol. Cell, 2019; 30: 778–793HaghandishN.BaldwinR.M.MorettinA.DawitH.T.AdhikaryH.MassonJ.Y.MazrouiR.Trinkle-MulcahyL.CôtéJ.PRMT7 methylates eukaryotic translation initiation factor 2α and regulates its role in stress granule formationMol. Biol. Cell20193077879310.1091/mbc.E18-05-0330658977630699057Search in Google Scholar
Han H.S., Choi D., Choi S., Koo S.H.: Roles of protein arginine methyltransferases in the control of glucose metabolism. Endocrinol. Metab., 2014; 29: 435–440HanH.S.ChoiD.ChoiS.KooS.H.Roles of protein arginine methyltransferases in the control of glucose metabolismEndocrinol. Metab.20142943544010.3803/EnM.2014.29.4.435428503425559572Search in Google Scholar
Hernandez S., Dominko T.: Novel protein arginine methyltransferase 8 isoform is essential for cell proliferation. J. Cell Biochem., 2016; 117: 2056–2066HernandezS.DominkoT.Novel protein arginine methyltransferase 8 isoform is essential for cell proliferationJ. Cell Biochem.20161172056206610.1002/jcb.2550826851891Search in Google Scholar
Hernandez S.J., Dolivo D.M., Dominko T.: PRMT8 demonstrates variant-specific expression in cancer cells and correlates with patient survival in breast, ovarian and gastric cancer. Oncol. Lett., 2017; 13: 1938–1989HernandezS.J.DolivoD.M.DominkoT.PRMT8 demonstrates variant-specific expression in cancer cells and correlates with patient survival in breast, ovarian and gastric cancerOncol. Lett.2017131938198910.3892/ol.2017.5671540353928454353Search in Google Scholar
Hsu M.C., Pan M.R., Chu P.Y., Tsai Y.L., Tsai C.H., Shan Y.S., Chen L.T., Hung W.C.: Protein arginine methyltransferase 3 enhances chemoresistance in pancreatic cancer by methylating hnRNPA1 to increase ABCG2 expression. Cancers, 2018; 11: 8HsuM.C.PanM.R.ChuP.Y.TsaiY.L.TsaiC.H.ShanY.S.ChenL.T.HungW.C.Protein arginine methyltransferase 3 enhances chemoresistance in pancreatic cancer by methylating hnRNPA1 to increase ABCG2 expressionCancers201811810.3390/cancers11010008635658230577570Search in Google Scholar
Hu G., Wang X., Han Y., Wang P.: Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis. EXCLI J., 2018; 17: 1157–1166HuG.WangX.HanY.WangP.Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosisEXCLI J.20181711571166Search in Google Scholar
Hu H., Qian K., Ho M.C., Zheng Y.G.: Small molecule inhibitors of protein arginine methyltransferases. Expert Opin. Investig. Drugs, 2016; 25: 335–358HuH.QianK.HoM.C.ZhengY.G.Small molecule inhibitors of protein arginine methyltransferasesExpert Opin. Investig. Drugs20162533535810.1517/13543784.2016.1144747492906226789238Search in Google Scholar
Iderzorig T., Kellen J., Osude C., Singh S., Woodman J.A., Garcia C., Puri N.: Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC. Biochem. Biophys. Res. Commun., 2018; 496: 770–777IderzorigT.KellenJ.OsudeC.SinghS.WoodmanJ.A.GarciaC.PuriN.Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLCBiochem. Biophys. Res. Commun.201849677077710.1016/j.bbrc.2018.01.069580120829337056Search in Google Scholar
Jahan S., Davie J.R.: Protein arginine methyltransferases (PRMTs): Role in chromatin organization. Adv. Biol. Regul., 2015; 57: 173–184JahanS.DavieJ.R.Protein arginine methyltransferases (PRMTs): Role in chromatin organizationAdv. Biol. Regul.20155717318410.1016/j.jbior.2014.09.00325263650Search in Google Scholar
Kaniskan H.Ü., Eram M.S., Liu J., Smil D., Martini M.L., Shen Y., Santhakumar V., Brown P.J., Arrowsmith C.H., Vedadi M., Jin J.: Design and synthesis of selective, small molecule inhibitors od coactivator-associated arginine methyltransferase 1 (CARM1). Med. Chem. Commun., 2016; 7: 1793–1796KaniskanH.Ü.EramM.S.LiuJ.SmilD.MartiniM.L.ShenY.SanthakumarV.BrownP.J.ArrowsmithC.H.VedadiM.JinJ.Design and synthesis of selective, small molecule inhibitors od coactivator-associated arginine methyltransferase 1 (CARM1)Med. Chem. Commun.201671793179610.1039/C6MD00342G519877828042453Search in Google Scholar
Karkhanis V., Hu Y.J., Baiocchi R.A., Imbalzano A.N., Sif S.: Versatility of PRMT5-induced methylation in growth control and development. Trends. Biochem. Sci., 2011; 36: 633–641KarkhanisV.HuY.J.BaiocchiR.A.ImbalzanoA.N.SifS.Versatility of PRMT5-induced methylation in growth control and developmentTrends. Biochem. Sci.20113663364110.1016/j.tibs.2011.09.001322548421975038Search in Google Scholar
Kleinschmidt M.A., de Graaf P., van Teeffeln H.A., Timmers H.T.: Cell cycle regulation by the PRMT6 arginine methyltransferase through repression of cyclin-dependent kinase inhibitors. PLoS One, 2012; 7: e41446KleinschmidtM.A.de GraafP.van TeeffelnH.A.TimmersH.T.Cell cycle regulation by the PRMT6 arginine methyltransferase through repression of cyclin-dependent kinase inhibitorsPLoS One20127e4144610.1371/journal.pone.0041446342339722916108Search in Google Scholar
Lattouf H., Poulard C., Le Romancer M.: PRMT5 prognostic value in cancer. Oncotarget, 2019; 10: 3151–3153LattoufH.PoulardC.Le RomancerM.PRMT5 prognostic value in cancerOncotarget2019103151315310.18632/oncotarget.26883651671431139329Search in Google Scholar
Leipold A., Heß J., Zaoui K.: Das Epigenoom. Zielstruktur für innovative Therapiekonzepte beim Kopf- und Halskarzinom. HNO, 2015; 63: 786–791LeipoldA.HeßJ.ZaouiK.Das Epigenoom. Zielstruktur für innovative Therapiekonzepte beim Kopf- und HalskarzinomHNO20156378679110.1007/s00106-015-0075-926489412Search in Google Scholar
Li M., An W., Xu L., Lin Y., Su L., Liu X.: The arginine methyl transferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLARL in human lung cancer cells. J. Exp. Clin. Cancer Res., 2019; 38: 64LiM.AnW.XuL.LinY.SuL.LiuX.The arginine methyl transferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLARL in human lung cancer cellsJ. Exp. Clin. Cancer Res.2019386410.1186/s13046-019-1064-8636874530736843Search in Google Scholar
Li S., Cheng D., Zhu B., Yang Q.: The overexpression of CARM1 promotes human osteosarcoma cell proliferation through the pGSK3β/β-catenin/cyclinD1 signaling pathway. Int. J. Biol. Sci., 2017; 13: 976–984LiS.ChengD.ZhuB.YangQ.The overexpression of CARM1 promotes human osteosarcoma cell proliferation through the pGSK3β/β-catenin/cyclinD1 signaling pathwayInt. J. Biol. Sci.20171397698410.7150/ijbs.19191559990328924379Search in Google Scholar
Li X., Wang C., Jiang H., Luo C.: A patent review of arginine methyltransferase inhibitors (2010–2018). Expert Opin. Ther. Pat., 2019; 29: 97–114LiX.WangC.JiangH.LuoC.A patent review of arginine methyltransferase inhibitors (2010–2018)Expert Opin. Ther. Pat.2019299711410.1080/13543776.2019.156771130640571Search in Google Scholar
Li Y., Zhu R., Wang W., Fu D., Hou J., Ji S., Chen B., Hu Z., Shao X., Yu X., Zhao Q., Zhang B., Du C., Bu Q., Hu C. i wsp.: Arginine methyltransferase 1 in the nucleus accumbens regulates behavioral effects of cocaine. J. Neurosci., 2015; 35: 12890–12902LiY.ZhuR.WangW.FuD.HouJ.JiS.ChenB.HuZ.ShaoX.YuX.ZhaoQ.ZhangB.DuC.BuQ.HuC.Arginine methyltransferase 1 in the nucleus accumbens regulates behavioral effects of cocaineJ. Neurosci.201535128901290210.1523/JNEUROSCI.0246-15.2015679519926377474Search in Google Scholar
Lin H., Wang B., Yu J., Wang J., Li Q., Cao B.: Protein arginine methyl transferase 8 gene enhances the colon cancer stem cell (CSC) function by upregulating the pluripotency transcription factor. J. Cancer, 2018; 9: 1394–1402LinH.WangB.YuJ.WangJ.LiQ.CaoB.Protein arginine methyl transferase 8 gene enhances the colon cancer stem cell (CSC) function by upregulating the pluripotency transcription factorJ. Cancer201891394140210.7150/jca.23835592908429721049Search in Google Scholar
Litt M., Qiu Y., Huang S.: Histone arginine methylations: Their roles in chromatin dynamics and transcriptional regulation. Biosci. Rep., 2009; 29: 131–141LittM.QiuY.HuangS.Histone arginine methylations: Their roles in chromatin dynamics and transcriptional regulationBiosci. Rep.20092913114110.1042/BSR20080176543380019220199Search in Google Scholar
Mann M., Zou Y., Chen Y., Brann D., Vadlamudi R.: PELP1 oncogenic functions involve alternative splicing via PRMT6. Mol. Oncol., 2014; 8: 389–400MannM.ZouY.ChenY.BrannD.VadlamudiR.PELP1 oncogenic functions involve alternative splicing via PRMT6Mol. Oncol.2014838940010.1016/j.molonc.2013.12.012394368924447537Search in Google Scholar
Michalak E.M., Visvader J.E.: Dysregulation of histone methyltransferases in breast cancer – opportunities for new targeted therapies? Mol. Oncol., 2016; 10: 1497–1515MichalakE.M.VisvaderJ.E.Dysregulation of histone methyltransferases in breast cancer – opportunities for new targeted therapies?Mol. Oncol.2016101497151510.1016/j.molonc.2016.09.003542313627717710Search in Google Scholar
Nakai K., Xia W., Liao H.W., Saito M., Hung M.C., Yamaguchi H.: The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. Breast Cancer, 2018; 25: 74–80NakaiK.XiaW.LiaoH.W.SaitoM.HungM.C.YamaguchiH.The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cellsBreast Cancer201825748010.1007/s12282-017-0790-z28643125Search in Google Scholar
Nakakido M., Deng Z., Suzuki T., Dohmae N., Nakamura Y., Hamamoto R.: PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents. Oncotarget, 2015; 6: 30957–30967NakakidoM.DengZ.SuzukiT.DohmaeN.NakamuraY.HamamotoR.PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agentsOncotarget20156309573096710.18632/oncotarget.5143474158026436589Search in Google Scholar
Nakayama K., Szewczyk M.M., Dela Sena C., Wu H., Dong A., Zeng H., Li F., de Freitas R.F., Eram M.S., Schapira M., Baba Y., Kunitomo M., Cary D.R., Tawada M., Ohashi A. i wsp.: TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma. Oncotarget, 2018; 9: 18480–18493NakayamaK.SzewczykM.M.Dela SenaC.WuH.DongA.ZengH.LiF.de FreitasR.F.EramM.S.SchapiraM.BabaY.KunitomoM.CaryD.R.TawadaM.OhashiA.TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myelomaOncotarget20189184801849310.18632/oncotarget.24883591508629719619Search in Google Scholar
Obianyo O., Causey C.P., Jones J.E., Thompson P.R.: Activity-based protein profiling of protein arginine methyltransferase 1. ACS Chem. Biol., 2011; 6: 1127–1135ObianyoO.CauseyC.P.JonesJ.E.ThompsonP.R.Activity-based protein profiling of protein arginine methyltransferase 1ACS Chem. Biol.201161127113510.1021/cb2001473319928621838253Search in Google Scholar
Pawlicka K., Perrigue P., Barciszewski J.: Epigenetyczna kontrola procesów komórkowych. Nauka, 2018; 2: 115–128PawlickaK.PerrigueP.BarciszewskiJ.Epigenetyczna kontrola procesów komórkowychNauka20182115128Search in Google Scholar
Peng C., Wong C.C.: The story of protein arginine methylation: Characterization, regulation, and function. Expert Rev. Proteomics, 2017; 14: 157–170PengC.WongC.C.The story of protein arginine methylation: Characterization, regulation, and functionExpert Rev. Proteomics20171415717010.1080/14789450.2017.127557328043171Search in Google Scholar
Poulard C., Corbo L., Le Romancer M.: Protein arginine methylation/demethylation and cancer. Oncotarget, 2016; 7: 67532–67550PoulardC.CorboL.Le RomancerM.Protein arginine methylation/demethylation and cancerOncotarget20167675326755010.18632/oncotarget.11376534189527556302Search in Google Scholar
Prabhu L., Chen L., Wei H., Demir Ö., Safa A., Zeng L., Amaro R.E., O’Neil B.H., Zhang Z.Y., Lu T.: Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases. Mol. Biosyst., 2017; 13: 2509–2520PrabhuL.ChenL.WeiH.DemirÖ.SafaA.ZengL.AmaroR.E.O’NeilB.H.ZhangZ.Y.LuT.Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferasesMol. Biosyst.2017132509252010.1039/C7MB00391A575932329099132Search in Google Scholar
Ran T., Li W., Peng B., Xie B., Lu T., Lu S., Liu W.: Virtual screening with a structure-based pharmacophore model to identify small-molecule inhibitors of CARM1. J. Chem. Inf. Model., 2019; 59: 522–534RanT.LiW.PengB.XieB.LuT.LuS.LiuW.Virtual screening with a structure-based pharmacophore model to identify small-molecule inhibitors of CARM1J. Chem. Inf. Model.20195952253410.1021/acs.jcim.8b0061030607947Search in Google Scholar
Ryu J.W., Kim S.K., Son M.Y., Jeon S.J., Oh J.H., Lim J.H., Cho S., Jung C.R., Hamamoto R., Kim D.S., Cho H.S.: Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC. Oncotarget, 2017; 8: 115444–115455RyuJ.W.KimS.K.SonM.Y.JeonS.J.OhJ.H.LimJ.H.ChoS.JungC.R.HamamotoR.KimD.S.ChoH.S.Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCCOncotarget2017811544411545510.18632/oncotarget.23296577778429383172Search in Google Scholar
Shailesh H., Zakaria Z.Z., Baiocchi R., Sif S.: Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer. Oncotarget, 2018; 9: 36705–36718ShaileshH.ZakariaZ.Z.BaiocchiR.SifS.Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancerOncotarget20189367053671810.18632/oncotarget.26404629117330613353Search in Google Scholar
Shen Y., Zhong J., Liu J., Liu K., Zhao J., Xu T., Zeng T., Li Z., Chen Y., Ding W., Wen G., Zu X., Cao R.: Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36. Oncol. Rep., 2018; 39: 2604–2612ShenY.ZhongJ.LiuJ.LiuK.ZhaoJ.XuT.ZengT.LiZ.ChenY.DingW.WenG.ZuX.CaoR.Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36Oncol. Rep.20183926042612Search in Google Scholar
Smith E., Zhou W., Shindiapina P., Sif S., Li C., Baiocchi R.A.: Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. Expert Opin. Ther. Targets, 2018; 22: 527–545SmithE.ZhouW.ShindiapinaP.SifS.LiC.BaiocchiR.A.Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapyExpert Opin. Ther. Targets20182252754510.1080/14728222.2018.1474203631170529781349Search in Google Scholar
Stopa N., Krebs J.E., Shechter D.: The PRMT5 arginine methyl transferase: Many roles in development, cancer and beyond. Cell Mol. Life. Sci., 2015; 72: 2041–2059StopaN.KrebsJ.E.ShechterD.The PRMT5 arginine methyl transferase: Many roles in development, cancer and beyondCell Mol. Life. Sci.2015722041205910.1007/s00018-015-1847-9443036825662273Search in Google Scholar
Tewary S.K., Zheng Y.G., Ho M.C.: Protein arginine methyltransferases: Insights into the enzyme structure and mechanism at the atomic level. Cell. Mol. Life Sci., 2019; 76: 2917–2932TewaryS.K.ZhengY.G.HoM.C.Protein arginine methyltransferases: Insights into the enzyme structure and mechanism at the atomic levelCell. Mol. Life Sci.2019762917293210.1007/s00018-019-03145-x674177731123777Search in Google Scholar
Vhuiyan M., Thomas D., Hossen F., Frankel A.: Targeting protein arginine N-methyltransferases with peptide-based inhibitors: Opportunities and challenges. Future Med. Chem., 2013; 5: 2199–2206VhuiyanM.ThomasD.HossenF.FrankelA.Targeting protein arginine N-methyltransferases with peptide-based inhibitors: Opportunities and challengesFuture Med. Chem.201352199220610.4155/fmc.13.18424261895Search in Google Scholar
Wang S.M., Dowhan D.H., Muscat G.E.: Epigenetic arginine methylation in breast cancer: Emerging therapeutic strategies. J. Mol. Endocrinol., 2019; 62: R223–R237WangS.M.DowhanD.H.MuscatG.E.Epigenetic arginine methylation in breast cancer: Emerging therapeutic strategiesJ. Mol. Endocrinol.201962R223R23710.1530/JME-18-022430620710Search in Google Scholar
Wang W.J., Hsu J.M., Wang Y.N., Lee H.H., Yamaguchi H., Liao H.W., Hung M.C.: An essential role of PRMT1-mediated EGFR methylation in EGFR activation by ribonuclease 5. Am. J. Cancer Res., 2019; 9: 180–185WangW.J.HsuJ.M.WangY.N.LeeH.H.YamaguchiH.LiaoH.W.HungM.C.An essential role of PRMT1-mediated EGFR methylation in EGFR activation by ribonuclease 5Am. J. Cancer Res.20199180185Search in Google Scholar
Wang Y.P., Zhou W., Wang J., Hung X., Zuo Y., Wang T.S., Gao X., Xu Y.Y., Zou S.W., Liu Y.B., Cheng J.K., Lei Q.Y.: Arginine methylation of MDH1 by CARM1 inhibits glutamine metabolism and suppresses pancreatic cancer. Mol. Cell, 2016; 64: 673–687WangY.P.ZhouW.WangJ.HungX.ZuoY.WangT.S.GaoX.XuY.Y.ZouS.W.LiuY.B.ChengJ.K.LeiQ.Y.Arginine methylation of MDH1 by CARM1 inhibits glutamine metabolism and suppresses pancreatic cancerMol. Cell20166467368710.1016/j.molcel.2016.09.02827840030Search in Google Scholar
Webb L.M., Amici S.A., Jablonski K.A., Savardekar H., Panfil A.R., Li L., Zhou W., Peine K., Karkhanis V., Bachelder E.M., Ainslie K.M., Green P.L., Li C., Baiocchi R.A., Gueraude-Arellano M.: PRMT5-selective inhibitors suppress inflammatory T cell responses and experimental autoimmune encephalomyelitis. J. Immunol., 2017; 198:1439–1451WebbL.M.AmiciS.A.JablonskiK.A.SavardekarH.PanfilA.R.LiL.ZhouW.PeineK.KarkhanisV.BachelderE.M.AinslieK.M.GreenP.L.LiC.BaiocchiR.A.Gueraude-ArellanoM.PRMT5-selective inhibitors suppress inflammatory T cell responses and experimental autoimmune encephalomyelitisJ. Immunol.20171981439145110.4049/jimmunol.1601702529258728087667Search in Google Scholar
Ye F., Zhang W., Ye F., Zhang W., Ye X., Jin J., Lv Z., Luo C.: Identification of selective, cell active inhibitors of protein arginine methyltransferase 5 through structure-based virtual screening and biological assays. J. Chem. Inf. Model., 2018; 58: 1066–1073YeF.ZhangW.YeF.ZhangW.YeX.JinJ.LvZ.LuoC.Identification of selective, cell active inhibitors of protein arginine methyltransferase 5 through structure-based virtual screening and biological assaysJ. Chem. Inf. Model.2018581066107310.1021/acs.jcim.8b0005029672052Search in Google Scholar
Ye Y., Zhang B., Mao R., Zhang C., Wang Y., Xing J., Liu Y.C., Luo X., Ding H., Yang Y., Zhou B., Jiang H., Chen K., Luo C., Zheng M.: Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening. Org. Biomol. Chem., 2017; 15: 3648–3661YeY.ZhangB.MaoR.ZhangC.WangY.XingJ.LiuY.C.LuoX.DingH.YangY.ZhouB.JiangH.ChenK.LuoC.ZhengM.Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screeningOrg. Biomol. Chem.2017153648366110.1039/C7OB00070GSearch in Google Scholar
Yost J.M., Korboukh I., Liu F., Gao C., Jin J.: Targets in epigenetics: Inhibiting the methyl writers of the histone code. Curr. Chem. Genomics, 2011; 5: 72–84YostJ.M.KorboukhI.LiuF.GaoC.JinJ.Targets in epigenetics: Inhibiting the methyl writers of the histone codeCurr. Chem. Genomics20115728410.2174/1875397301005010072317889621966347Search in Google Scholar
Zhang B., Chen X., Ge S., Peng C., Zhang S., Chen X., Liu T., Zhang W.: Arginine methyltransferase inhibitor-1 inhibits sarcoma viability in vitro and in vivo. Oncol. Lett., 2018; 16: 2161–2166ZhangB.ChenX.GeS.PengC.ZhangS.ChenX.LiuT.ZhangW.Arginine methyltransferase inhibitor-1 inhibits sarcoma viability in vitro and in vivoOncol. Lett.2018162161216610.3892/ol.2018.8929603647730008914Search in Google Scholar
Zhang B., Zhang S., Zhu L., Chen X., Zhao Y., Chao L., Zhou J., Wang X., Zhang X., Ma N.: Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5. Toxicol. Appl. Pharmacol., 2017; 336: 1–7ZhangB.ZhangS.ZhuL.ChenX.ZhaoY.ChaoL.ZhouJ.WangX.ZhangX.MaN.Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5Toxicol. Appl. Pharmacol.20173361710.1016/j.taap.2017.10.00228987382Search in Google Scholar
Zhao X., Zhou D., Liu Y., Li C., Zhao X., Li Y., Li W.: Ganoderma lucidum polysaccharide inhibits prostate cancer cell migration via the protein arginine methyltransferase 6 signaling pathway. Mol. Med. Rep., 2018; 17: 147–157ZhaoX.ZhouD.LiuY.LiC.ZhaoX.LiY.LiW.Ganoderma lucidum polysaccharide inhibits prostate cancer cell migration via the protein arginine methyltransferase 6 signaling pathwayMol. Med. Rep.20181714715710.3892/mmr.2017.7904578008529115463Search in Google Scholar
Zhao Y., Lu Q., Li C., Wang X., Jiang L., Huang L., Wang C., Chen H.: PRMT1 regulates the tumour-initiating properties of esophageal squamous cell carcinoma through histone H4 arginine methylation coupled with transcriptional activation. Cell Death. Dis., 2019; 10: 359ZhaoY.LuQ.LiC.WangX.JiangL.HuangL.WangC.ChenH.PRMT1 regulates the tumour-initiating properties of esophageal squamous cell carcinoma through histone H4 arginine methylation coupled with transcriptional activationCell Death. Dis.20191035910.1038/s41419-019-1595-0649484431043582Search in Google Scholar
Zhong J., Cao R.X., Hong T., Yang J., Zu X.Y., Xiao X.H., Liu J.H., Wen G.B.: Identification and expression analysis of a novel transcript of the human PRMT2 gene resulted from alternative polyadenylation in breast cancer. Gene, 2011; 487: 1–9ZhongJ.CaoR.X.HongT.YangJ.ZuX.Y.XiaoX.H.LiuJ.H.WenG.B.Identification and expression analysis of a novel transcript of the human PRMT2 gene resulted from alternative polyadenylation in breast cancerGene20114871910.1016/j.gene.2011.06.02221820040Search in Google Scholar
Zhong J., Cao R.X., Liu J.H., Liu Y.B., Wang J., Liu L.P., Chen Y.J., Yang J., Zhang Q.H., Wu Y., Ding W.J., Hong T., Xiao X.H., Zu X.Y., Wen G.B.: Nuclear loss of protein arginine N-methyltransferase 2 in breast carcinoma is associated with tumor grade and overexpression of cyclin D1 protein. Oncogene, 2014; 33: 5546–5558ZhongJ.CaoR.X.LiuJ.H.LiuY.B.WangJ.LiuL.P.ChenY.J.YangJ.ZhangQ.H.WuY.DingW.J.HongT.XiaoX.H.ZuX.Y.WenG.B.Nuclear loss of protein arginine N-methyltransferase 2 in breast carcinoma is associated with tumor grade and overexpression of cyclin D1 proteinOncogene2014335546555810.1038/onc.2013.50024292672Search in Google Scholar
Zhong J., Chen Y.J., Chen L., Shen Y.Y., Zhang Q.H., Yang J., Cao R.X., Zu X.Y., Wen G.B.: PRMT2β, a C-terminal splice variant of PRMT2β, inhibits the growth of breast cancer cells. Oncol. Rep., 2017, 38: 1303–1311ZhongJ.ChenY.J.ChenL.ShenY.Y.ZhangQ.H.YangJ.CaoR.X.ZuX.Y.WenG.B.PRMT2β, a C-terminal splice variant of PRMT2β, inhibits the growth of breast cancer cellsOncol. Rep.2017381303131110.3892/or.2017.578628677794Search in Google Scholar
Zhong X.Y., Yuan X.M., Xu Y.Y., Yin M., Yan W.W., Zou S.W., Wei L.M., Lu H.J., Wang Y.P., Lei Q.Y.: CARM1 methylates GAPDH to regulate glucose metabolism and is suppressed in liver cancer. Cell. Rep., 2018; 24: 3207–3223ZhongX.Y.YuanX.M.XuY.Y.YinM.YanW.W.ZouS.W.WeiL.M.LuH.J.WangY.P.LeiQ.Y.CARM1 methylates GAPDH to regulate glucose metabolism and is suppressed in liver cancerCell. Rep.2018243207322310.1016/j.celrep.2018.08.06630232003Search in Google Scholar
Zhu K., Jiang C., Tao H., Liu J., Zhang H., Luo C.: Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations. Bioorg. Med. Chem. Lett., 2018; 28: 1476–1483ZhuK.JiangC.TaoH.LiuJ.ZhangH.LuoC.Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluationsBioorg. Med. Chem. Lett.2018281476148310.1016/j.bmcl.2018.03.08729628326Search in Google Scholar